Neuralstem Inc. (CUR)

1.82
NASDAQ : Health Technology
Prev Close 1.73
Day Low/High 1.65 / 1.89
52 Wk Low/High 1.62 / 27.40
Avg Volume 177.90K
Exchange NASDAQ
Shares Outstanding 3.69M
Market Cap 6.38M
EPS -6.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Neuralstem Closes $7.5 Million Underwritten Public Offering

Neuralstem Closes $7.5 Million Underwritten Public Offering

GERMANTOWN, Md., July 31, 2019 /PRNewswire/ -- Neuralstem, Inc.

Neuralstem Announces Pricing Of $7.5 Million Underwritten Public Offering

Neuralstem Announces Pricing Of $7.5 Million Underwritten Public Offering

GERMANTOWN, Md., July 25, 2019 /PRNewswire/ -- Neuralstem, Inc.

Neuralstem Appoints Mary Ann Gray, Ph.D., To Board Of Directors

Neuralstem Appoints Mary Ann Gray, Ph.D., To Board Of Directors

GERMANTOWN, Md., July 18, 2019 /PRNewswire/ -- Neuralstem, Inc.

Neuralstem Announces A 1-for-20 Reverse Stock Split

Neuralstem Announces A 1-for-20 Reverse Stock Split

GERMANTOWN, Md., July 16, 2019 /PRNewswire/ -- Neuralstem, Inc.

Neuralstem Announces Issuance Of New Patent Covering Broad Therapeutic Use Of Neural Stem Cells

Neuralstem Announces Issuance Of New Patent Covering Broad Therapeutic Use Of Neural Stem Cells

GERMANTOWN, Md., May 16, 2019 /PRNewswire/ -- Neuralstem, Inc.

Neuralstem Reports First Quarter 2019 Fiscal Results

Neuralstem Reports First Quarter 2019 Fiscal Results

- Kenneth C. Carter, PhD appointed Executive Chairman

Neuralstem Appoints David J. Mazzo, Ph.D., To Board Of Directors

Neuralstem Appoints David J. Mazzo, Ph.D., To Board Of Directors

GERMANTOWN, Md., May 6, 2019 /PRNewswire/ -- Neuralstem, Inc.

First Week Of CUR February 2019 Options Trading

First Week Of CUR February 2019 Options Trading

Investors in Neuralstem Inc saw new options begin trading this week, for the February 2019 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 189 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Intra-Cellular Leaps; Schizophrenia Drug Shows Less Side Effects-Biotech Movers

Intra-Cellular Leaps; Schizophrenia Drug Shows Less Side Effects-Biotech Movers

Standard treatments can cause motor side effects and/or weight gain, cardiovascular complications, dyslipidemia, and hyperglycemia.

TheStreet Quant Rating: D- (Sell)